NIA

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Monday, April 1, 2024
Lewy body, Research, GBA, Administration, Plasma, Conference, MRI, DLB, GFAP, Basal forebrain, Patient, Journal, Chairperson, Sale, TID, Manuscript, Public expenditure, Biomarker, Glial fibrillary acidic protein, MD, University College London, Atrophy, Publication, Frontotemporal dementia, Alpha-synuclein, NIA, Research and development, Vertex Pharmaceuticals, Axonal transport, Dementia, CRVO

BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported its financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Moreover, the neflamapimod treatment effects on GFAP were correlated to clinical outcomes, assessed by the CDR-SB.
  • Cash Position: As of December 31, 2023, CervoMed had $7.8 million in cash and cash equivalents as compared to $4.1 million as of December 31, 2022.
  • This increase was attributed to the RewinD-LB Phase 2b clinical study in DLB which began in the first quarter of 2023.
  • Net Loss: Net Loss was $2.2 million for the year ended December 31, 2023, compared to a net loss of $5.8 million for year ended December 31, 2022.

Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 26, 2024
Research, Corporation, Conference, DLB, Alzheimer's disease, Disease, Biomarker, Public expenditure, Translational Neurodegeneration, Completeness, Vance DeGeneres, Protein, Clinical trial, Quantitative electroencephalography, Therapy, NIA, SHIMMER, Cognition, Pharmaceutical industry

PURCHASE, N.Y., March 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update. Management will host a live webcast conference call at 8:00am ET to review 2023 accomplishments. Details of the call are provided below.

Key Points: 
  • ET -
    PURCHASE, N.Y., March 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
  • Cognition scientists published two manuscripts and made 11 presentations at medical and scientific congresses in 2023, advancing the understanding of its foundational science and clinical implications.
  • “We achieved a number of critical clinical objectives in 2023,” said Lisa Ricciardi, Cognition’s president and CEO .
  • Management will host a conference call and live webcast to discuss Cognition’s financial results today at 8:00 a.m.

Thought Leaders, Entrepreneurs and Active Investors Come Together to Shape Innovation at the 21st Annual What's Next Longevity Venture Summit

Retrieved on: 
Tuesday, April 9, 2024
Dark, Fairmont San Francisco, Head, Conference, MFA, Longevity, AARP, Government, Learning, Growth, Incubator, Running, AI, Investment banking, Ziegler, Housing, Summit, NIA, National Institute on Aging

LAFAYETTE, Calif., April 9, 2024 /PRNewswire/ -- Mary Furlong & Associates (MFA), producer of the longest running conference on the longevity economy, announced that the What's Next Longevity Venture Summit, will bring together thought leaders, including active investors, entrepreneurs, incubators, nonprofits, government agencies, providers and companies focused on the $9.5 trillion longevity market, June 11-12 at the Fairmont San Francisco. The theme, Net New: Investment, AI & Innovation In the Longevity Marketplace, will drive discussions on the key challenges and opportunities for those supporting the age 50+ market.

Key Points: 
  • The theme, Net New: Investment, AI & Innovation In the Longevity Marketplace, will drive discussions on the key challenges and opportunities for those supporting the age 50+ market.
  • "We put a laser focus on the active investors in the space today, highlighting the investment opportunities as well as forming partnerships for success in longevity.
  • And, to demonstrate their continued commitment to the Summit, the AgeTech Collaborative from AARP will be the title sponsor of this year's conference."
  • The What's Next Longevity Venture Summit will take place at the Fairmont San Francisco, June 11-12.

Congress Passes Bills Making Major Investments in Alzheimer’s

Retrieved on: 
Saturday, March 23, 2024
Congress, Medical imaging, Caregiver, Health equity, DSM-IV codes, Research, National Institute on Aging, National coverage determination, Investment, CDC, NINDS, Language, Dementia, NIA, Medicare, NCD, CMS, Pharmaceutical industry

WASHINGTON, March 23, 2024 (GLOBE NEWSWIRE) -- As part of a budget bill heading to President Biden for his signature, Congress passed major investments in the fight against Alzheimer’s; specifically demonstrating its unwavering commitment to equity and inclusion in the reporting language, which helps to foster a more equitable and just healthcare system.

Key Points: 
  • WASHINGTON, March 23, 2024 (GLOBE NEWSWIRE) -- As part of a budget bill heading to President Biden for his signature, Congress passed major investments in the fight against Alzheimer’s; specifically demonstrating its unwavering commitment to equity and inclusion in the reporting language, which helps to foster a more equitable and just healthcare system.
  • “We are thrilled to witness Congress’s steadfast 12-year commitment to Alzheimer’s research, despite ongoing budget restraints,” said UsAgainstAlzheimer’s chair and co-founder George Vradenburg.
  • UsAgainstAlzheimer’s worked to include language encouraging diversity in clinical trials, and the establishment of a brain health equity initiative to improve the integration of brain health into primary care, particularly within underrepresented communities.
  • The bill also encourages the National Institute of Biomedical Imaging and Bioengineering to collaborate with National Institute of Aging (NIA) and The National Institute of Neurological Disorders and Stroke (NINDS) to develop new technologies that could discover the earliest biological events that lead to Alzheimer’s disease and related dementias.

The University of Texas Health Science Center at San Antonio announces the passing of William L. Henrich, MD, president since 2009

Retrieved on: 
Friday, March 15, 2024
Alzheimer's disease, Barshop Institute, Biomedical Research, Health, Patient, History, Quality of life, Humour, University, MACP, Love, NIA, Pandemic, Dementia, Ageing, NCI, Obesity, Innovation, UT System, Diabetes, SAN, NIH, Workforce, Transplant, Intelligence, Public, FACP, Integration, News, Textbook, Cancer, Dialysis, Haematopoietic system, Family, Neurodegenerative disease, Dentistry, Growth, COVID-19, School, Life, University of Texas System, MARC, Nursing

SAN ANTONIO, Texas, March 14, 2024 /PRNewswire-PRWeb/ -- It is with profound sadness that The University of Texas of Health Science Center at San Antonio (UT Health San Antonio) announces that William L. Henrich, MD, MACP, president of UT Health San Antonio, passed away this morning, March 14, 2024. There will be announcements about Dr. Henrich's memorial services soon.

Key Points: 
  • SAN ANTONIO, Texas, March 14, 2024 /PRNewswire-PRWeb/ -- It is with profound sadness that The University of Texas of Health Science Center at San Antonio (UT Health San Antonio) announces that William L. Henrich, MD, MACP, president of UT Health San Antonio, passed away this morning, March 14, 2024.
  • Dr. Henrich was able to return as president in February 2013 and presided over the unprecedented growth experienced by UT Health San Antonio.
  • The University of Texas Health Science Center at San Antonio (UT Health San Antonio), a primary driver of San Antonio's $44.1 billion health care and biosciences sector, is the largest academic research institution in South Texas with an annual research portfolio of $413 million.
  • Monica Taylor, The University of Texas Health Science Center at San Antonio, 210-450-8970, [email protected] , https://news.uthscsa.edu/

Gravitrex Wins National Institute on Aging Startup Challenge

Retrieved on: 
Friday, February 23, 2024
Bangladesh Technical Education Board, Burns, Entrepreneurship, NIH, Quality of life, NIA, Hospital, Health, Startup company, Mentorship, Disability, Walking, Death, BWS, Disease, Research

PHOENIX, Feb. 23, 2024 /PRNewswire-PRWeb/ -- Gravitrex, a rehabilitation technology startup, today announced that it won the National Institute on Aging (NIA) Startup Challenge to advance commercialization of its radically new walking-assist device, that will increase access to walking rehabilitation for older adults after hospitalization or a fall. This prestigious award validates the potential of Gravitrex's innovative technology to significantly impact health outcomes for older adults.

Key Points: 
  • PHOENIX, Feb. 23, 2024 /PRNewswire-PRWeb/ -- Gravitrex , a rehabilitation technology startup, today announced that it won the National Institute on Aging (NIA) Startup Challenge to advance commercialization of its radically new walking-assist device, that will increase access to walking rehabilitation for older adults after hospitalization or a fall.
  • -Kira Burns, Co-founder & CEO
    NIA is a division of The National Institutes of Health (NIH) and the Startup challenge supports products aimed at improving the health and quality of life for older adults in minority and underserved populations.
  • Burns added, "We would like to extend our deepest gratitude to the National Institute on Aging for this award, and for the significant investment in resources committed during the entire Startup Challenge Program.
  • We are confident that NIA's investment in the Startup Challenge will lead to the commercialization of multiple technologies that will positively impact health outcomes for older adults in underserved populations."

UT Health San Antonio doctors among first to implant rechargeable deep brain stimulation device

Retrieved on: 
Thursday, February 15, 2024
Electrode, University of Texas System, SAN, School, DSM-IV codes, Alzheimer's disease, Nursing, Neurosurgery, College, Research, Education, MD, Teaching hospital, University, Quality of life, Food, Sleep, DBS, NIA, Tremor, Risk, Neurodegenerative disease, Parkinson's disease, Contract management, Health, Movement disorder, Patient, News, Electricity, Epilepsy, Longevity, Movement, Workforce, Long School, Brain

SAN ANTONIO, Feb. 15, 2024 /PRNewswire-PRWeb/ -- Doctors at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) are among the nation's first to implant a newly approved sensing rechargeable deep brain stimulation device with a 15-year battery life allowing more continual treatment of patients with movement disorders.

Key Points: 
  • SAN ANTONIO, Feb. 15, 2024 /PRNewswire-PRWeb/ -- Doctors at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) are among the nation's first to implant a newly approved sensing rechargeable deep brain stimulation device with a 15-year battery life allowing more continual treatment of patients with movement disorders.
  • Deep brain stimulation, known as DBS, is the placement of electrodes in the brain connected to a battery-operated generator in the chest similar to a cardiac pacemaker.
  • Note: Neither UT Health San Antonio nor University Health endorses commercial products or services by name.
  • The University of Texas Health Science Center at San Antonio (UT Health San Antonio), a primary driver of San Antonio's $44.1 billion health care and biosciences sector, is the largest academic research institution in South Texas with an annual research portfolio of $413 million.

Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging

Retrieved on: 
Tuesday, February 13, 2024
Research, Doctor of Philosophy, Dementia, MD, Public health, NIA, Medicine, LNTH, Non-fungible token, University, PET, Positron emission tomography, Medical imaging

BEDFORD, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced a collaboration agreement with a National Institute on Aging (NIA)-sponsored study called the Consortium for Clarity in ADRD Research Through Imaging (CLARiTI). This agreement enables the consortium to use MK-6240, Lantheus’ clinical-stage F18-labeled Positron Emission Tomography (PET) imaging agent, in its investigation of Alzheimer’s disease and related dementias. MK-6240 targets aggregated tau protein in the form of neurofibrillary tangles (NFTs) which are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.

Key Points: 
  • This agreement enables the consortium to use MK-6240, Lantheus’ clinical-stage F18-labeled Positron Emission Tomography (PET) imaging agent, in its investigation of Alzheimer’s disease and related dementias.
  • MK-6240 targets aggregated tau protein in the form of neurofibrillary tangles (NFTs) which are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.
  • “We are thrilled to partner with Lantheus to use MK-6240 for tau PET imaging in this important study.”
    “MK-6240 is poised to play a pivotal role in propelling Alzheimer’s diagnosis and treatment research to new heights,” said Jean-Claude Provost, MD, Chief Medical Officer, Lantheus.
  • “This agreement aligns with Lantheus’ purpose to actively cultivate collaborations that empower researchers worldwide with essential tools to accelerate clinical research and development of therapies.

ACES Expands Strategic Partnerships - Announces Contract with Noida International Airport

Retrieved on: 
Thursday, February 1, 2024
Partnership, NIA, ACES, Noida International Airport, Dot, Data infrastructure, Rail transport

NEW DELHI, Feb. 1, 2024 /PRNewswire/ -- ACES India Private Limited, a fully owned subsidiary of Advanced Communications & Electronic Systems Company (ACES-Saudi Arabia), a leading International Neutral Digital Infrastructure Company proudly announces a monumental stride in its expansion, the signing of a 10 years contract with Noida International Airport (NIA).

Key Points: 
  • NEW DELHI, Feb. 1, 2024 /PRNewswire/ -- ACES India Private Limited, a fully owned subsidiary of Advanced Communications & Electronic Systems Company (ACES-Saudi Arabia), a leading International Neutral Digital Infrastructure Company proudly announces a monumental stride in its expansion, the signing of a 10 years contract with Noida International Airport (NIA).
  • This momentous occasion signifies the culmination of thorough deliberation, mutual understanding, and shared vision between ACES and NIA.
  • The agreement solidifies ACES' commitment for delivering cutting-edge 4G and 5G Mobile Infrastructure (as per DoT guidelines) at the airport.
  • ACES is a leading Neutral Digital Infrastructure company with rich global experience and our partnership will be instrumental in powering the digital experience at Noida International Airport."

ACES Expands Strategic Partnerships - Announces Contract with Noida International Airport

Retrieved on: 
Thursday, February 1, 2024
Partnership, NIA, ACES, Noida International Airport, Dot, Data infrastructure, Rail transport

NEW DELHI, Feb. 1, 2024 /PRNewswire/ -- ACES India Private Limited, a fully owned subsidiary of Advanced Communications & Electronic Systems Company (ACES-Saudi Arabia), a leading International Neutral Digital Infrastructure Company proudly announces a monumental stride in its expansion, the signing of a 10 years contract with Noida International Airport (NIA).

Key Points: 
  • NEW DELHI, Feb. 1, 2024 /PRNewswire/ -- ACES India Private Limited, a fully owned subsidiary of Advanced Communications & Electronic Systems Company (ACES-Saudi Arabia), a leading International Neutral Digital Infrastructure Company proudly announces a monumental stride in its expansion, the signing of a 10 years contract with Noida International Airport (NIA).
  • This momentous occasion signifies the culmination of thorough deliberation, mutual understanding, and shared vision between ACES and NIA.
  • The agreement solidifies ACES' commitment for delivering cutting-edge 4G and 5G Mobile Infrastructure (as per DoT guidelines) at the airport.
  • ACES is a leading Neutral Digital Infrastructure company with rich global experience and our partnership will be instrumental in powering the digital experience at Noida International Airport."